Companies · Other
CANOGA PARK · Other
Diligence memoA one-page analyst read on Med-X, Inc. — recommendation, valuation, rhythm, risks.→Med-X, Inc. looks over-valued against its niche peers and is active on financing cadence.
Synthesized from the figures below est. — every claim rests on a number shown on this page.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
No named principal in this company's public records yet — see all operators below.
Explore how these operators interlock with other companies in the operator network.
Med-X, Inc. is one of 25008 Other companies tracked from CANOGA PARK. By capital raised it ranks in the upper tier (ahead of 82% of sector peers), and mid-pack by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.
Round size and date are reported; the stage label is inferred from round size (latest is Series A — a $4.0M–$15M round). Valuation is modeled from stage benchmarks. Directional, not a quoted figure.
Benchmarked against 25008 companies in Other. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 82% of sector peers (real $). Modeled value above 64% of peers (estimate).
A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #85 of 485.
| Company | Stage | Raised · real | Value · est | vs peer med. |
|---|---|---|---|---|
| Sea Court GP, LLC | Series A | $15.0M | $57.7M | 2.98× |
| Kastle Biopartners II LP | Series A | $14.4M | $53.1M | 2.75× |
| Econic Investment LLC | Series A | $14.0M | $53.1M | 2.74× |
| DCFC Holdings, LLC | Series A | $16.1M | $51.8M | 2.67× |
| HeadVantage Corp | Series A | $15.0M | $50.8M | 2.62× |
| Cobbs Creek Restoration & Community Foundation | Series A | $14.1M | $50.5M | 2.61× |
| Mawson Resources Ltd | Series A | $26.3M | $50.2M | 2.60× |
| Chess Champion Ltd Liability Co | Series A | $15.0M | $50.1M | 2.59× |
| Sepratech TopCo, LLC | Series A | $14.6M | $49.7M | 2.57× |
| MATT & LEWIS DEVELOPMENT Ltd LIABILITY Co | Series A | $15.0M | $48.6M | 2.51× |
| FlyGuys, Inc | Series A | $16.7M | $48.5M | 2.51× |
| Empyrean Club, LLC | Series A | $14.0M | $48.0M | 2.48× |
| Med-X, Inc. this company | Series A | $15.2M | $32.5M | 1.68× |
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Pre-Seed | $229K | 2018-02-02 | $1.3M | $5.3M | 90% |
| Pre-Seed | $467K | 2019-03-12 | $2.6M | $10.8M | 90% |
| Pre-Seed | $467K | 2019-03-12 | $2.6M | $10.8M | 90% |
| Pre-Seed | $600K | 2020-03-26 | $3.3M | $13.9M | 90% |
| Pre-Seed | $225K | 2021-04-02 | $1.3M | $3.7M | 90% |
| Seed | $1.2M | 2021-10-01 | $6.0M | $14.0M | 90% |
| Seed | $100K | 2022-10-28 | $500K | $783K | 90% |
| Seed | $120K | 2023-05-06 | $600K | $775K | 90% |
| Seed | $100K | 2024-02-27 | $500K | $477K | 90% |
| Seed | $838K | 2024-05-14 | $4.2M | $3.7M | 90% |
| Seed | $250K | 2024-05-14 | $1.3M | $1.1M | 90% |
| Seed | $838K | 2024-09-17 | $4.2M | $3.3M | 90% |
| Pre-Seed | $428K | 2025-01-23 | $2.4M | $1.3M | 90% |
| Seed | $428K | 2025-01-23 | $2.1M | $1.5M | 90% |
| Seed | $250K | 2025-06-03 | $1.3M | $746K | 90% |
| Series A | $10.3M | 2025-09-26 | $47.0M | $32.5M | 90% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.
| Person | Role | Also runs | Tied since |
|---|---|---|---|
| MATTHEW MILLS | — | 4 other | 2018-02 |
| DAVID TOOMEY | — | 2 other | 2018-02 |
| JENNIFER MILLS | — | 2 other | 2018-02 |
| Michael Kuntz | — | 2 other | 2022-10 |
| ALLAN KURTZ | — | 1 other | 2018-02 |
| FRED DASHIELL, JR. | — | 1 other | 2021-04 |
| RON TCHORZEWSKI | — | 1 other | 2018-02 |
| FRED ALLAN DASHIELL, JR. | — | — | 2024-05 |
| FREDERICK DASHIELL JR. | — | — | 2019-03 |
| MARY KAY WILSON | — | — | 2025-09 |
| MORTON HYSON | — | — | 2018-02 |
| NICHOLAS PHILLIPS | — | — | 2024-02 |
| RONALD TCHORZEWSKI | — | — | 2021-04 |
Med-X, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| Pacific Shore Holdings, Inc. | Retailing | Seed | $7.7M | $5.3M | network6 shared operators |
| Hannah's LLC | Other | Series A | $15.1M | $31.4M | same sector · same stage |
| SystImmune, Inc. | Other | Series A | $15.1M | $32.9M | same sector · same stage |
| Murphy's Naturals, Inc. | Other | Series A | $15.2M | $32.8M | same sector · same stage |
| GoingOn Networks Inc | Other | Series A | $15.0M | $34.1M | same sector · same stage |
| GlyEco, Inc. | Other | Series A | $15.4M | $31.8M | same sector · same stage |
| dappHero Corp. | Other | Series A | $15.6M | $31.3M | same sector · same stage |
| Nada Holdings, Inc. | Other | Series A | $14.8M | $31.4M | same sector · same stage |
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| MedRx Global, Inc. | Other Health Care | Pre-Seed | $27.7M | 86% |
| Special X, Inc. | Other | Series A | $75.7M | 86% |
| Medico CX, Inc. | Other Health Care | Pre-Seed | $10.1M | 86% |
| Medplace, Inc. | Other | Seed | $26.3M | 85% |
| Optical X, Inc. | Other Health Care | Seed | $7.6M | 85% |
| MedaSync Inc. | Other | Seed | $7.6M | 85% |
| BioMedx Group, Inc. | Other Health Care | Pre-Seed | $14.0M | 85% |
| Mediflix Inc. | Other Technology | Seed | $38.3M | 85% |
See where Med-X, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at Med-X, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.